Polyvalent Emoxypine Derivatives Disaggregate Alpha-Synuclein

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Parkinson's disease, such as levodopa, have significant side effects and are not effective in modifying the disease progression, highlighting the need for more effective therapies that target the underlying pathophysiology of synucleinopathies.

Innovation Solution

Administration of polyvalent derivatives of emoxypine, specifically poly-imino or poly-amido emoxypine derivatives, which effectively disaggregate alpha-synuclein aggregates, thereby treating or preventing synucleinopathies like Parkinson's disease.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If levodopa is used to treat Parkinson's disease, then motor symptoms are temporarily relieved, but side effects increase and disease progression is not modified

Engineering Contradiction:

Improvesymptom relief effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and targets the specific pathological mechanism (alpha-synuclein aggregation) rather than treating general dopamine deficiency. By using polyvalent emoxypine derivatives that specifically bind to and disaggregate alpha-synuclein aggregates, the treatment addresses the root cause while avoiding the broad metabolic effects of levodopa that cause side effects.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The polyvalent emoxypine derivatives act as intermediary agents that facilitate the disaggregation of alpha-synuclein aggregates. These compounds serve as mediators between the therapeutic goal (reducing aggregation) and the pathological target (alpha-synuclein), providing a mechanism that is more specific and controllable than direct dopamine replacement.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If levodopa is used to treat Parkinson's disease, then motor symptoms are temporarily relieved, but disease progression modification is not achieved

Engineering Contradiction:

Improvesymptom relief effectivenessVSAvoiddisease progression modification

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent employs preliminary action by targeting and disaggregating alpha-synuclein aggregates before they can cause irreversible neuronal damage and disease progression. By interfering with the aggregation process early, the treatment prevents the formation of Lewy bodies and their toxic effects on dopaminergic neurons, thereby modifying disease course rather than just treating symptoms.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent converts the harmful aggregated alpha-synuclein into a beneficial target for therapeutic intervention. By designing compounds that specifically recognize and disaggregate these aggregates, the treatment transforms the pathological feature (aggregation) into the basis for a disease-modifying therapy that prevents further aggregation and neuronal damage.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Reliability

If polyvalent emoxypine derivatives are used to disaggregate alpha-synuclein, then aggregation is reduced, but selectivity against beta-amyloid must be maintained

Engineering Contradiction:

Improvealpha-synuclein disaggregation efficacyVSAvoidaggregate type selectivity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by designing polyvalent emoxypine derivatives with specific structural features that confer selectivity for alpha-synuclein over beta-amyloid. The compounds have localized binding sites and molecular characteristics that match the specific structural properties of alpha-synuclein aggregates, allowing them to discriminate between different aggregate types and act only on the intended target.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS12290510B2Polyvalent derivatives of emoxypine

Publication Date: 2025.05.06 PRIAVOID GMBH

AI summary

Use of polyvalent emoxypine derivatives or related compounds in the treatment or prevention of, inter alia, Parkinson's Disease are described.